N/A
Completed N=35
Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans
Healthy
Source: ClinicalTrials.gov NCT02051426 ↗
Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Nov 2014
Primary outcomePrimary: Change in Visual Analogue Scale (VAS) of Anxiety - From Baseline to 2 Hours — 0.5; 0.0 units on a scale
Summary
The efficacy of compounds having agonistic activity at the glycine site associated with the N-methyl-D-aspartate receptor (NMDAR) is presently assessed in psychiatric disorders. In contrast to NMDAR antagonists, the neuropsychiatric effects of NMDAR agonists in the healthy human organism are not known. The investigators studied neuropsychiatric and neurochemical effects of the NMDAR-glycine site obligatory co-agonist D-serine (DSR) in healthy subjects using a randomized, controlled crossover challenge design including a baseline assessment day and two treatment administration days (DSR and placebo in randomized order). Thirty-five subjects aged 23-29 years participated in the study and received a 2.1g orally administered DSR dose. The main outcome measures were the changes in scores of mood-related Visual Analogue Scale (VAS), Continuous Performance Test - Identical Pairs (CPT-IP), and Rey Auditory Verbal Learning Test (RAVLT).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Visual Analogue Scale (VAS) of Anxiety - From Baseline to 2 Hours |
0.5; 0.0 | — |
| PRIMARY Change in Cognitive Function- CPT-IP D-prime Score - From Baseline to 2 Hours |
.5; 0 | — |
| PRIMARY Change in Rey Auditory Verbal Learning Test RAVLT (Trial 7) - From Baseline to 2 Hours |
2; .3 | — |
Eligibility Criteria
Inclusion Criteria
- healthy volunteers
Exclusion Criteria
- history of psychiatric, medical, neurological illness or substance abuse
Data sourced from ClinicalTrials.gov (NCT02051426). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.